Compound library / Research / Investigational
Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that increases endogenous EPO production by mimicking altitude adaptation; approved in China, Japan, and Europe for anemia in CKD. Explored for endurance enhancement.
| Category | Research / Investigational |
|---|---|
| Typical route | Oral |
| Half-life | ~9-12 hours |
| Common dose range | 70-200 mg 3x/week (clinical CKD dosing); non-clinical dosing not established |
| Typical cycle length | Ongoing under supervision for CKD; not established for performance use |
BioHack Track models Roxadustat (Evrenzo) at a half-life of 10.5 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Oral tablet; no reconstitution needed.
Store at room temperature.
Not FDA-approved. WADA-prohibited. Can cause thromboembolic events and hypertension; acts on multiple HIF-regulated pathways beyond just red blood cell production — widespread effects poorly characterized at performance doses.
Track Roxadustat (Evrenzo) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Roxadustat (Evrenzo) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.